Trial · NCT00023595
Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease
NCT00023595, Phase 3, Completed, Duke University; results first posted 2017-07-24
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease. Trials, record NCT00023595. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00023595
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease
- NCT number
- NCT00023595
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 2,136 participants, actual
- Lead sponsor
- Duke University
- Conditions
- Cardiovascular Diseases, Coronary Disease, Heart Failure, Congestive, Heart Diseases
- Interventions
- CABG surgery plus MED, Active Medication Alone, CABG plus MED and SVR
- First posted
- 2001-09-11
- Last updated
- 2019-09-19
- Results first posted
- 2017-07-24
Source ClinicalTrials.gov
Registered outcomes101
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | H01: All Cause Mortality | 5 years post randomization | |
| Primary | H01: All Cause Mortality | 10 years post randomization | |
| Primary | H02: All-cause Mortality or Cardiovascular Hospitalization | 5 years post randomization | |
| Secondary | H01: Cardiovascular Mortality (Defined as Sudden Death or Death Attributed to Recurrent MI, HF, a Cardiovascular Procedure, Stroke, or Other Cardiovascular Etiology). | 10 years post randomization | |
| Secondary | H01: Cardiovascular Mortality (Defined as Sudden Death or Death Attributed to Recurrent MI, HF, a Cardiovascular Procedure, Stroke, or Other Cardiovascular Etiology). | 5 years post randomization | |
| Secondary | H01: Mortality or Cardiovascular Hospitalization | up to 5 years post randomization | |
| Secondary | H01: Mortality or Cardiovascular Hospitalization | up to 10 years post randomization | |
| Secondary | H02: All-cause Mortality | up to 5 years | |
| Secondary | H01: All-cause Mortality Within 30 Days After Randomization | 30 days post randomization | |
| Secondary | H02: All-cause Mortality Within 30 Days After Randomization | 30 days post randomization |
1 to 10 of 101Source ClinicalTrials.gov
See all 101 registered outcomesOutcomes101
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | H01: All Cause Mortality | 5 years post randomization | The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm. | participants | NUMBER |
| PRIMARY | H01: All Cause Mortality | 10 years post randomization | The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm. | participants | NUMBER |
| PRIMARY | H02: All-cause Mortality or Cardiovascular Hospitalization | 5 years post randomization | The Total H02: Medication + CABG group includes the H02: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm. | participants | NUMBER |
| SECONDARY | H01: Cardiovascular Mortality (Defined as Sudden Death or Death Attributed to Recurrent MI, HF, a Cardiovascular Procedure, Stroke, or Other Cardiovascular Etiology). | 10 years post randomization | The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm. | participants | NUMBER |
| SECONDARY | H01: Cardiovascular Mortality (Defined as Sudden Death or Death Attributed to Recurrent MI, HF, a Cardiovascular Procedure, Stroke, or Other Cardiovascular Etiology). | 5 years post randomization | The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm. | participants | NUMBER |
| SECONDARY | H01: Mortality or Cardiovascular Hospitalization | up to 5 years post randomization | The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm. | participants | NUMBER |
| SECONDARY | H01: Mortality or Cardiovascular Hospitalization | up to 10 years post randomization | The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm. | participants | NUMBER |
| SECONDARY | H02: All-cause Mortality | up to 5 years | The Total H02: Medication + CABG group includes the H02: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm. | participants | NUMBER |
| SECONDARY | H01: All-cause Mortality Within 30 Days After Randomization | 30 days post randomization | The Total H01: Medication + CABG group includes the H01: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm. | participants | NUMBER |
| SECONDARY | H02: All-cause Mortality Within 30 Days After Randomization | 30 days post randomization | The Total H02: Medication + CABG group includes the H02: Medication + CABG group and those 76 patients who belong to H01+H02: Medication + CABG arm | participants | NUMBER |
1 to 10 of 101Source ClinicalTrials.gov
See all 101 outcomesResults by group690
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| H01: All Cause Mortality | H01: Medication | 244 | participants | ||
| H01: All Cause Mortality | Total H01: Medication + CABG | 218 | participants | ||
| H01: All Cause Mortality | H01: Medication | 398 | participants | ||
| H01: All Cause Mortality | Total H01: Medication + CABG | 359 | participants | ||
| H02: All-cause Mortality or Cardiovascular Hospitalization | H02: Medication+CABG+SVR | 289 | participants | ||
| H02: All-cause Mortality or Cardiovascular Hospitalization | Total H02: Medication+CABG | 292 | participants | ||
| H01: Cardiovascular Mortality (Defined as Sudden Death or Death Attributed to Recurrent MI, HF, a Cardiovascular Procedure, Stroke, or Other Cardiovascular Etiology). | Total H01: Medication + CABG | 247 | participants | ||
| H01: Cardiovascular Mortality (Defined as Sudden Death or Death Attributed to Recurrent MI, HF, a Cardiovascular Procedure, Stroke, or Other Cardiovascular Etiology). | H01: Medication | 297 | participants | ||
| H01: Cardiovascular Mortality (Defined as Sudden Death or Death Attributed to Recurrent MI, HF, a Cardiovascular Procedure, Stroke, or Other Cardiovascular Etiology). | Total H01: Medication + CABG | 168 | participants | ||
| H01: Cardiovascular Mortality (Defined as Sudden Death or Death Attributed to Recurrent MI, HF, a Cardiovascular Procedure, Stroke, or Other Cardiovascular Etiology). | H01: Medication | 201 | participants |
1 to 10 of 690Source ClinicalTrials.gov
See all 690 results by groupParticipant flow30
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| 5 Year Follow up | STARTED | H01: Medication | 602 | |
| 5 Year Follow up | STARTED | H01: Medication + CABG | 534 | |
| 5 Year Follow up | STARTED | H01+H02: Medication + CABG | 76 | |
| 5 Year Follow up | STARTED | H02: Medication+CABG | 423 | |
| 5 Year Follow up | STARTED | H02: Medication+CABG+SVR | 501 | |
| 5 Year Follow up | COMPLETED | H01: Medication | 600 | |
| 5 Year Follow up | COMPLETED | H01: Medication + CABG | 532 | |
| 5 Year Follow up | COMPLETED | H01+H02: Medication + CABG | 75 | |
| 5 Year Follow up | COMPLETED | H02: Medication+CABG | 416 | |
| 5 Year Follow up | COMPLETED | H02: Medication+CABG+SVR | 498 |
1 to 10 of 30Source ClinicalTrials.gov
See all 30 participant flowAdverse events710
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | ABSCESS | Infections and infestations | H01: Medication | 0 | 602 | |
| serious | ABSCESS | Infections and infestations | H01: Medication + CABG | 0 | 534 | |
| serious | ABSCESS | Infections and infestations | H01 & H02: Medication+CABG | 0 | 76 | |
| serious | ABSCESS | Infections and infestations | H02: Medication+CABG | 0 | 423 | |
| serious | ABSCESS | Infections and infestations | H02: Medication+CABG+SVR | 1 | 501 | |
| serious | ACUTE CORONARY SYNDROME | Cardiac disorders | H01: Medication | 1 | 602 | |
| serious | ACUTE CORONARY SYNDROME | Cardiac disorders | H01: Medication + CABG | 0 | 534 | |
| serious | ACUTE CORONARY SYNDROME | Cardiac disorders | H01 & H02: Medication+CABG | 0 | 76 | |
| serious | ACUTE CORONARY SYNDROME | Cardiac disorders | H02: Medication+CABG | 0 | 423 | |
| serious | ACUTE CORONARY SYNDROME | Cardiac disorders | H02: Medication+CABG+SVR | 0 | 501 |
1 to 10 of 710Source ClinicalTrials.gov
See all 710 adverse eventsAdverse event totals15
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | H01: Medication | ||
| Total, all-cause mortality | H01: Medication + CABG | ||
| Total, all-cause mortality | H01 & H02: Medication+CABG | ||
| Total, all-cause mortality | H02: Medication+CABG | ||
| Total, all-cause mortality | H02: Medication+CABG+SVR | ||
| Total, other adverse events | H01: Medication | 0 | 0 |
| Total, other adverse events | H01: Medication + CABG | 0 | 0 |
| Total, other adverse events | H01 & H02: Medication+CABG | 0 | 0 |
| Total, other adverse events | H02: Medication+CABG | 0 | 0 |
| Total, other adverse events | H02: Medication+CABG+SVR | 0 | 0 |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 adverse event totalsPapers36
The papers the trial lists on ClinicalTrials.gov.
Grants8
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|---|---|---|---|---|---|
| R01HL105853 | STICHES | AL-KHALIDI, HUSSEIN | DUKE UNIVERSITY | NATIONAL HEART, LUNG, AND BLOOD INSTITUTE | 2011 to 2015 | NIH RePORTER |
| U01HL069015 | STICH Trial-Coordinating Center | JONES, ROBERT H | DUKE UNIVERSITY | NATIONAL HEART, LUNG, AND BLOOD INSTITUTE | 2002 to 2011 | NIH RePORTER |
| U01HL069013 | STICH Trial-Statistical and Data Coordinatiing Center | LEE, KERRY L | DUKE UNIVERSITY | NATIONAL HEART, LUNG, AND BLOOD INSTITUTE | 2002 to 2010 | NIH RePORTER |
| U01HL069011 | STICH TRIAL- Economics & Quality of Life Core Laboratory | MARK, DANIEL B | DUKE UNIVERSITY | NATIONAL HEART, LUNG, AND BLOOD INSTITUTE | 2002 to 2008 | NIH RePORTER |
| U01HL069009 | STICH TRIAL - NEUROHORMONAL/ CYTOKINE/ GENETIC CORE LAB | FELDMAN, ARTHUR M | THOMAS JEFFERSON UNIVERSITY | NATIONAL HEART, LUNG, AND BLOOD INSTITUTE | 2002 to 2007 | NIH RePORTER |
| U01HL069010 | STICH Trial-Echocardiographic Core Laboratory | OH, JAE K | MAYO CLINIC ROCHESTER | NATIONAL HEART, LUNG, AND BLOOD INSTITUTE | 2002 to 2007 | NIH RePORTER |
| U01HL069012 | STICH Trial Radionuclide Core Laboratory | BONOW, ROBERT O | NORTHWESTERN UNIVERSITY AT CHICAGO | NATIONAL HEART, LUNG, AND BLOOD INSTITUTE | 2002 to 2007 | NIH RePORTER |
| U01HL072683 | STICH-Trial Cardiovascular Magenetic Resonance Core Lab | POHOST, GERALD MICHAEL | UNIVERSITY OF SOUTHERN CALIFORNIA | NATIONAL HEART, LUNG, AND BLOOD INSTITUTE | 2002 to 2007 | NIH RePORTER |
Trial comparisons37
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| H01: Medication vs Total H01: Medication + CABG: H01: All Cause Mortality | Trial comparisons |
| H01: Medication vs Total H01: Medication + CABG: H01: All-cause Mortality Within 30 Days After Randomization | Trial comparisons |
| H01: Medication vs Total H01: Medication + CABG: H01: Mortality or Cardiovascular Hospitalization | Trial comparisons |
| H01: Medication vs Total H01: Medication + CABG: H01: All-cause (Unplanned and Elective) Hospitalization | Trial comparisons |
| H01: Medication vs Total H01: Medication + CABG: H01: Stroke | Trial comparisons |
| H01: Medication vs Total H01: Medication + CABG: H01: All-cause Mortality or Revascularization (CABG or PCI) | Trial comparisons |
| H01: Medication vs Total H01: Medication + CABG: H01: Cardiac Procedure: Implantable Cardioverter Defibrillator (ICD) | Trial comparisons |
| H01: Medication vs Total H01: Medication + CABG: H01: All-cause Mortality, Heart Transplant or LVAD | Trial comparisons |
| H01: Medication vs Total H01: Medication + CABG: H01: Mortality or Cardiovascular Hospitalization | Trial comparisons |
| H01: Medication vs Total H01: Medication + CABG: H01: Stroke | Trial comparisons |
1 to 10 of 37
See all 37 trial comparisonsTests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00023595
GET https://conductscience.org/api/trials/v1/NCT00023595/registered?page=2